Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 10 2022
26 10 2022
Historique:
received:
27
07
2022
accepted:
11
10
2022
entrez:
26
10
2022
pubmed:
27
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Ferritin is frequently used to screen some dire consequences of iron overload in β-thalassemia patients. The study aimed to define the best cutoff point of ferritin to screen for cardiac and liver hemosiderosis in these cases. This was a registry-based study on β-thalassemia patients living throughout Mazandaran province, Iran (n = 1959). In this diagnostic research, the index test was ferritin levels measured by a chemiluminescent immunoassay. As a reference test, T2*-weighted magnetic resonance imaging (T2*-weighted MRI) was applied to determine cardiac and liver hemosiderosis. A cutoff point of 2027 ng/mL for ferritin showed a sensitivity of 50%, specificity 77.4%, PPV 42.1%, and NPV 82.5% for cardiac hemosiderosis (area under curve [AUC] 0.66, 95% CI 0.60-0.71, adjusted odds ratio [OR] 2.05, 95% CI 1.05-4.01). At an optimum cutoff point of 1090 ng/mL, sensitivity 66.7%, specificity 68%, PPV 82.9%, and NPV 46.8% for liver hemosiderosis were estimated (AUC 0.68, 95% CI 0.63-0.73, adjusted OR 3.93, 95% CI 2.02-7.64. The likelihood of cardiac hemosiderosis serum ferritin levels below 2027 ng/mL is 17.5%. Moreover, 82.9% of β-thalassemia patients with serum ferritin levels above 1090 ng/mL may suffer from liver hemosiderosis, regardless of the grades.
Identifiants
pubmed: 36289264
doi: 10.1038/s41598-022-22234-9
pii: 10.1038/s41598-022-22234-9
pmc: PMC9606378
doi:
Substances chimiques
Ferritins
9007-73-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17996Informations de copyright
© 2022. The Author(s).
Références
Pediatr Hematol Oncol. 2014 Oct;31(7):583-96
pubmed: 25247665
Ann N Y Acad Sci. 2010 Aug;1202:31-5
pubmed: 20712769
Pol J Radiol. 2019 May 30;84:e262-e268
pubmed: 31481999
Transfus Clin Biol. 2022 May;29(2):153-160
pubmed: 34856399
Iran Red Crescent Med J. 2015 Apr 25;17(4):e24959
pubmed: 26023341
Molecules. 2020 Apr 24;25(8):
pubmed: 32344579
Am J Hematol. 2021 Nov 1;96(11):1518-1531
pubmed: 34347889
Pediatr Res. 2022 Jun;91(7):1709-1714
pubmed: 34903834
Br J Haematol. 2000 Sep;110(4):971-7
pubmed: 11054091
Br J Haematol. 2018 Jul;182(2):301-305
pubmed: 28543061
Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004839
pubmed: 23966105
East Mediterr Health J. 2013 Aug;19(8):727-32
pubmed: 24975358
Adv Clin Exp Med. 2020 Apr;29(4):475-480
pubmed: 32369274
Pediatr Hematol Oncol. 2017 Aug;34(5):292-297
pubmed: 29190176
Magn Reson Imaging Clin N Am. 2010 Aug;18(3):359-81, ix
pubmed: 21094445
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
Haematologica. 2011 Jan;96(1):41-7
pubmed: 20884710
Crit Care. 2019 Mar 9;23(1):81
pubmed: 30850005
Haematologica. 2008 Oct;93(10):1584-6
pubmed: 18728025
Eur J Intern Med. 2011 Feb;22(1):62-5
pubmed: 21238896
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):210-5
pubmed: 25696857
Lancet. 2022 Jun 18;399(10343):2310-2324
pubmed: 35691301
Postgrad Med. 2019 May;131(4):261-267
pubmed: 31002266
Sci Rep. 2020 Dec 3;10(1):21164
pubmed: 33273639
N Engl J Med. 1994 Sep 1;331(9):574-8
pubmed: 8047081
Ann Hematol. 2010 Jun;89(6):585-9
pubmed: 20016898
N Engl J Med. 2022 Feb 3;386(5):415-427
pubmed: 34891223
Acta Cardiol Sin. 2016 Mar;32(2):231-8
pubmed: 27122954
Arch Iran Med. 2016 Feb;19(2):96-100
pubmed: 26838079
Biology (Basel). 2022 Jan 17;11(1):
pubmed: 35053146
Blood. 2005 Aug 15;106(4):1460-5
pubmed: 15860670
Genet Med. 2010 Feb;12(2):61-76
pubmed: 20098328
Ann N Y Acad Sci. 2005;1054:40-7
pubmed: 16339650
Ann Hematol. 2019 Jun;98(6):1323-1331
pubmed: 30729283